In this appendix, the committee develops a first-order model that estimates health outcomes (measured as fraction of exposed individuals who survive) for any prepositioning strategy. For convenience of presentation, the term *survival* is used instead of *saved* to refer to those exposed individuals who have been protected from becoming symptomatic by timely prophylaxis with effective medical countermeasures (MCM). The model development is as follows.

1. ** = time between release (and, by assumption, exposure) and decision to dispense (DTD).** For any community, estimates of should ideally be informed by existing submodels that incorporate the capabilities of currently used (or planned) monitoring and surveillance systems, as well as data from past BioWatch Actionable Results, accidental releases, and drills, to estimate the various times contributing to the value of . These include the time:

• needed to deliver MCM from the nearest Strategic National Stockpile (SNS) location,

• required to determine clinically that at least one individual has been infected, and

• between positive diagnosis and the decision by the responsible public health authority to issue an order to dispense.

Note that in what follows, the assumption is made that all individuals will be exposed at the moment of release. This is an “optimistic” assumption,

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.

Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 237

Appendix C
First-Order Model
In this appendix, the committee develops a first-order model that esti-
mates health outcomes (measured as fraction of exposed individuals who
survive) for any prepositioning strategy. For convenience of presentation,
the term survival is used instead of saved to refer to those exposed indi-
viduals who have been protected from becoming symptomatic by timely
prophylaxis with effective medical countermeasures (MCM). The model
development is as follows.
1. δ = time between release (and, by assumption, exposure) and decision
to dispense (DTD). For any community, estimates of δ should ideally be
informed by existing submodels that incorporate the capabilities of cur-
rently used (or planned) monitoring and surveillance systems, as well as
data from past BioWatch Actionable Results, accidental releases, and drills,
to estimate the various times contributing to the value of δ. These include
the time:
• needed to deliver MCM from the nearest Strategic National Stock-
pile (SNS) location,
• required to determine clinically that at least one individual has been
infected, and
• between positive diagnosis and the decision by the responsible
public health authority to issue an order to dispense.
Note that in what follows, the assumption is made that all individuals will
be exposed at the moment of release. This is an “optimistic” assumption,
237

OCR for page 237

238 PREPOSITIONING ANTIBIOTICS FOR ANTHRAX
in the sense that individuals exposed later will not require prophylaxis as
soon as those exposed immediately and thus will fare better as a result of
any dispensing campaign.
2. X = for any particular individual, the time from DTD to that person’s
prophylaxis. The value of X is not just clearly different for each individual,
but is an uncertain quantity for any individual. In other words, for any
individual, X is a random variable.
3. The probability distribution Φ(x) for X can be interpreted to be either:
Φ(x) = probability that a randomly selected individual will experi-
•
ence a time X less than or equal to x, or, equivalently,
Φ(x) = the fraction of randomly selected individuals who will ex-
•
perience a time X less than or equal to x.
4. g = goal for the points of dispensing (PODs) for the time from start of
dispensing MCM to completion. Using the simplifying assumptions that the
size of the dispensing staff is constant, that staff are never idle, and that the
service time is constant at the PODs, it can readily be shown that, given the
goal g for the time from starting to completing dispensing, the distribution
function for X is uniform:
x
Φ ( x) = , 0≤x≤ g
g
with associated density function:
1
φ ( x) = , 0≤x≤ g
g
5. T = time from exposure to prophylaxis (TTP) = δ + X. It follows from
the definition of X that T is a random variable with probability density
function p(t), where
1
p (t ) = , δ ≤t ≤δ+g (1)
g
6. The survival function f(t) represents, for any particular release scenario,
one of the various incubation period curves or values discussed at length in
Chapter 2, where t is the time since exposure. As pointed out in Chapter 2,

OCR for page 237

239
APPENDIX C
data with which to compute this survival function are either uncertain or
limited, and the function will depend on many unknown scenario variables.
Nevertheless, to obtain insight into the potential health advantages of
prepositioning, the committee has taken the liberty of fitting f(t) to the sur-
vival data (based on the Sverdlosk release) presented by Wilkening (2006,
2008) and Brookmeyer et al. (2001, 2005). Using these data, f(t) can be
well fit, for values of t up to about 200 hours, by
2
f (t ) = e−(.004t )
This function can in turn be approximated (for t up to around 150 hours)
by
2
f (t ) = 1 − (.004t ) (2)
7. S = the expected fraction of the population that will survive a release, de-
scribed by a particular scenario, using a particular prepositioning strategy.
From the definition of f(t) and p(t), S can be computed from
S = ∫ f (t ) p (t ) dt
In particular, using the uniform distribution for p(t) given by equation (1)
yields:
δ+ g
1
∫ f (t ) dt
S= (3)
g
δ
Using the approximation for f(t) given by equation (2), S can then be ob-
tained analytically (for d + g <150 hours) from equation (3), yielding:
(.004) ((δ + g ) − δ 3 )
2 3
δ+ g
1
∫ (1− (.004t ) )dt = 1−
2
S= (4)
3g
g
δ
This equation is valid for g >0; since the practical realities of even the most
ideal strategy for predispensing to individuals will involve some finite delay,
for all practical purposes, g will never be exactly equal to 0.

OCR for page 237

240 PREPOSITIONING ANTIBIOTICS FOR ANTHRAX
REFERENCES
Brookmeyer, R., N. Blades, M. Hugh-Jones, and D. A. Henderson. 2001. The statistical
analysis of truncated data: Application to the Sverdlovsk anthrax outbreak. Biostatistics
2(2):233-247.
Brookmeyer, R., E. Johnson, and S. Barry. 2005. Statistics in Medicine 24(4):531-542.
Wilkening, D. A. 2006. Sverdlovsk revisited: Modeling human inhalation anthrax. Proceedings
of the National Academy of Sciences 103(20):7589-7594.
Wilkening, D. A. 2008. Modeling the incubation period of inhalational anthrax. Medical
Decision Making 28(4):593-605.